eyenovia-logo 3

Investor Relations

Investor Relations

Corporate Profile

Eyenovia is a late-stage ophthalmic biopharmaceutical company developing breakthrough treatments for front and back-of-the-eye diseases, which are made possible by the company’s transformative, high precision ophthalmic delivery platform. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed indications for presbyopia, myopia progression and mydriasis.

Presentation & Investor Materials

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Recent News Releases
08/11/21
Eyenovia Reports Second Quarter 2021 Financial Results
08/04/21
Eyenovia to Report Second Quarter 2021 Results on Wednesday, August 11
07/19/21
Eyenovia to Participate in a Presbyopia Panel Discussion at Eyecelerator 2021
Upcoming Events
There are currently no events scheduled.